Profile data is unavailable for this security.
About the company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
- Revenue in USD (TTM)0.00
- Net income in USD-13.04m
- Incorporated2004
- Employees12.00
- LocationKiora Pharmaceuticals Inc332 ENCINITAS BOULEVARD, SUITE 102ENCINITAS 92024United StatesUSA
- Phone+1 (781) 788-8869
- Fax+1 (302) 636-5454
- Websitehttps://kiorapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imunon Inc | 0.00 | -19.51m | 12.50m | 33.00 | -- | 0.9338 | -- | -- | -2.17 | -2.17 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -59.23 | -50.18 | -80.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Monopar Therapeutics Inc | 0.00 | -8.40m | 12.69m | 10.00 | -- | 1.94 | -- | -- | -0.612 | -0.612 | 0.00 | 0.3749 | 0.00 | -- | -- | 0.00 | -81.69 | -54.07 | -107.13 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.62m | 12.87m | 85.00 | -- | 0.4698 | -- | -- | -3.01 | -3.01 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -44.86 | -58.80 | -48.21 | -66.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.08 | -- | 16.04 | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -21.27m | 12.99m | 5.00 | -- | 2.95 | -- | -- | -0.8922 | -0.8922 | 0.00 | 0.1221 | 0.00 | -- | -- | 0.00 | -266.05 | -36.90 | -392.90 | -37.81 | -- | -- | -- | -- | -- | -- | 0.2068 | -- | -- | -- | 43.40 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.36m | 13.31m | 7.00 | -- | 1.15 | -- | -- | -0.8004 | -0.8004 | 0.00 | 0.9828 | 0.00 | -- | -- | 0.00 | -55.47 | -43.54 | -57.90 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Actavia Life Sciences Inc | 0.00 | -4.44m | 13.35m | 1.00 | -- | -- | -- | -- | -0.0074 | -0.0074 | 0.00 | -0.0027 | 0.00 | -- | -- | 0.00 | -10,235.89 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -21.20 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 13.47m | 233.00 | 0.0904 | 0.0014 | 3.49 | 0.1903 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 13.48m | 12.00 | -- | 0.6474 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Dominari Holdings Inc | 2.04m | -22.88m | 13.65m | 26.00 | -- | 0.2579 | -- | 6.69 | -4.44 | -4.44 | 0.3899 | 8.92 | 0.0305 | -- | 0.3829 | 78,423.08 | -34.20 | -26.82 | -35.10 | -27.45 | -- | -- | -1,122.22 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 13.70m | 46.00 | -- | 0.5121 | -- | 0.3201 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Nexgel Inc | 4.09m | -3.16m | 13.83m | 19.00 | -- | 2.71 | -- | 3.38 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 14.11m | 22.00 | -- | 2.55 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 01 Feb 2024 | 2.30m | 8.76% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 2.30m | 8.76% |
| Stonepine Capital Management LLCas of 31 Jan 2024 | 1.80m | 6.86% |
| Citadel Securities LLCas of 31 Dec 2023 | 92.59k | 0.35% |
| CapFinancial Partners LLCas of 31 Dec 2023 | 80.00k | 0.31% |
| Geode Capital Management LLCas of 31 Dec 2023 | 37.21k | 0.14% |
| Virtu Americas LLCas of 31 Dec 2023 | 28.44k | 0.11% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 24.57k | 0.09% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 18.70k | 0.07% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 14.46k | 0.06% |
